An exciting new oral agent has recently become available to treat patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel.
Abiraterone is an androgen biosynthesis inhibitor which acts at 3 sources of testosterone production: the testes, adrenal glands and prostate tumor tissue.
Hopefully, the indications for this once daily 250mg tablet will be expanded to include other patients who never received chemotherapy.
Excellent blog very nice and unique information related to ZYTIGA. Thanks for sharing this information.
ReplyDeleteKamagra
Its a good blog over treatment of BPH by Avodart. Avodart
ReplyDeleteIts a good blog over treatment of BPH by Avodart. Avodart
ReplyDelete